Valerie Shander
Family · New Brunswick, NJNPI 1205134533
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.6%), food and beverage and education — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Fresenius Kabi USA, LLC at 60.0% of the total. Reporting peaked in 2024 at $599 and has fallen 55.1% since, to $269 in 2025.
Across 13 payments — averaging $74.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fresenius Kabi USA, LLC$582
- E.r. Squibb & Sons, L.L.C.$113
- Gilead$92
- Pharmacyclics LLC, An Abbvie Company$88
- Stemline Therapeutics Inc.$29
- AstraZeneca$18
- plus $49 from 3 others
What the payments were for
- Consulting fees$54056%
- Food & beverage$35537%
- Education$768%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fresenius Kabi USA, LLC | 2 | $582 |
| E.r. Squibb & Sons, L.L.C. | 1 | $113 |
| Gilead | 2 | $92 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $88 |
| Stemline Therapeutics Inc. | 1 | $29 |
| AstraZeneca | 1 | $18 |
| Novartis | 1 | $18 |
| Puma Biotechnology, Inc. | 1 | $17 |
| Boston Scientific | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$971 in reported general payments places this provider in the 75th percentile of 2,692 family providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 19 | $11,091 |
| Letrozole | 110 | $2,881 |
| Tamoxifen Citrate | 43 | $747 |
| Dexamethasone | 28 | $364 |
| Gabapentin | 24 | $341 |
| Anastrozole | 30 | $314 |
| Prochlorperazine Maleate | 20 | $193 |
| Pantoprazole Sodium | 21 | $178 |
| Ondansetron Hcl | 25 | $170 |
| Tramadol Hcl | 14 | $117 |
Paid to pharmacies, not to this prescriber.
Other family in New Brunswick
- Tara McCabeNew Brunswick$22K
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
- Shawn DenningToms River$29K
- Kimberly ClementeEatontown$25K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.